Acumen Pharmaceuticals Valuation Multiples

Acumen Pharmaceuticals Overview

About Acumen Pharmaceuticals

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Founded

1996

HQ

Employees

61

Website

acumenpharm.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

EBITDA: ($124M)

EV

$96M

Valuation Multiples

Multiples.vc

Start free trial

Acumen Pharmaceuticals Financials

Acumen Pharmaceuticals reported last 12-month revenue of — and negative EBITDA of ($124M).

In the same LTM period, Acumen Pharmaceuticals generated — in gross profit, ($124M) in EBITDA losses, and had net loss of ($116M).

Acumen Pharmaceuticals P&L

In the most recent fiscal year, Acumen Pharmaceuticals reported revenue of — and EBITDA of ($117M).

Acumen Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Acumen Pharmaceuticals Stock Performance

Acumen Pharmaceuticals has current market cap of $182M, and enterprise value of $96M.

Acumen Pharmaceuticals' stock price is $2.52.

Acumen Pharmaceuticals Valuation Multiples

Acumen Pharmaceuticals trades at (0.8x) EV/EBITDA.

Acumen Pharmaceuticals Financial Valuation Multiples

As of April 11, 2026, Acumen Pharmaceuticals has market cap of $182M and EV of $96M.

Equity research analysts estimate Acumen Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Acumen Pharmaceuticals has a P/E ratio of (1.6x).

Acumen Pharmaceuticals Margins & Growth Rates

Acumen Pharmaceuticals' revenue in the last fiscal year grew by —.

Acumen Pharmaceuticals' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.0M for the same period.

Acumen Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Acumen Pharmaceuticals M&A Activity

Acumen Pharmaceuticals acquired XXX companies to date.

Last acquisition by Acumen Pharmaceuticals was on XXXXXXXX, XXXXX. Acumen Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Acumen Pharmaceuticals Investment Activity

Acumen Pharmaceuticals invested in XXX companies to date.

Acumen Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Acumen Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).